ReviewFrontiers in immunology2026
Research progress of OTUD7B: from structural function and disease mechanisms to clinical translation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OTUD7B (Cezanne), a deubiquitinase of the Ovarian Tumor (OTU) domain family, regulates the ubiquitin-proteasome system and plays a role in maintaining cellular homeostasis. Its dysfunction is linked to the pathogenesis of multiple human diseases. In neoplastic diseases, OTUD7B is overexpressed in several solid tumors, including non-small cell lung cancer (NSCLC), gastric cancer, breast cancer, and pancreatic cancer. It promotes tumor cell proliferation, invasion, metastasis, and chemoresistance by stabilizing oncoproteins such as YAP1, ERα, and β-catenin/LEF1. This stabilization activates signaling pathways including NF-κB, Wnt/β-catenin, and Notch. However, its function is context-dependent. In diffuse large B-cell lymphoma (DLBCL), OTUD7B stabilizes TRAF3 to inhibit the non-canonical NF-κB pathway. In hepatocellular carcinoma (HCC), it deubiquitinates and stabilizes p53 to induce apoptosis. In both contexts, high expression correlates with favorable prognosis. In non-neoplastic diseases, OTUD7B also plays a dual role. In experimental autoimmune encephalomyelitis (EAE) models, it protects neurons by deubiquitinating RIPK1 and stabilizing GFAP. This action suppresses inflammation and promotes glial scar formation. Conversely, in pathological cardiac hypertrophy, its role is model-dependent. It protects against ferroptosis by stabilizing HNF4α in pressure-overload models. Under neurohormonal stimulation, it promotes hypertrophy by deubiquitinating SERCA2a and disrupting calcium homeostasis. These findings indicate that OTUD7B is a context-specific regulator. Its expression levels are associated with prognosis in multiple diseases. It shows potential as a diagnostic and prognostic biomarker and as a therapeutic target for specific conditions. This review systematically summarizes the molecular characteristics, expression regulation, physiological functions, and mechanisms of OTUD7B in neoplastic and non-neoplastic diseases. It also discusses the prospects and challenges of its clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.